Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Z Best Place to Talk Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Larry S. who wrote (24918)	10/10/2000 8:36:40 AM
From: DanZ	Read Replies (1) \| Respond to of 53068

GUMM. Prominent Medical Journal to Publish Independent Clinical Study on Revolutionary OTC Cold Remedy Scientific Study Reveals Zicam(TM) Cold Remedy Reduced Duration of Common Cold by an Average of 75% PR NEWSWIRE - October 10, 2000 08:04 biz.yahoo.com This is one bit of news that I have been waiting for. IMO, more good news to come between now and the end of the year including the preventative clinical study and a partnership with a large pharmaceutical company. Publication in a reputable medical journal such as ENT is important because it adds credibility to the study results and puts the results in front of doctors who may now recommend Zicam to their patients. This will also allow Gum Tech to make specific claims with regard to reduction of duration and severity of the common cold in their advertising, and even refer to the journal publication. Hopefully this press release will also generate some free PR in the media.